|
Market Closed -
London S.E.
09:05:09 02/10/2026 pm IST
|
5-day change | 1st Jan Change | ||
| 1,779.50 GBX | -0.86% |
|
-3.86% | -2.47% |
| 02/10 | Major drugmakers turn to China for licensing deals | RE |
| 01/10 | GSK plc : JP Morgan reiterates its Sell rating | ZD |
| Market Cap | 7.13TCr 9.43TCr 8.38TCr 7.82TCr 13TCr 9,06900Cr 14TCr 95TCr 37TCr 4,63600Cr 35TCr 35TCr 14,87900Cr | P/E 2026 * |
13.8x | P/E 2027 * | 11.4x |
|---|---|---|---|---|---|
| Enterprise Value | 9.25TCr 12TCr 11TCr 10TCr 17TCr 11,77100Cr 18TCr 1,22900Cr 48TCr 6,01700Cr 46TCr 45TCr 19,31200Cr | EV / Sales 2026 * |
2.73x | EV / Sales 2027 * | 2.53x |
| Free-Float |
92.75% | Yield 2026 * |
3.91% | Yield 2027 * | 4.21% |
| Markets | Quality | ||
|---|---|---|---|
London S.E.
| GSK | Delayed | |
CBOE
| GSK | Real-time | |
|
Xetra
| GS71 | Delayed | |
|
Tradegate
| GS71 | Real-time | |
|
Boerse Muenchen
| GS71 | Real-time | |
|
OTC Markets
| GLAXF | Delayed | |
|
Börse Stuttgart
| GS71 | Delayed | |
|
Mexican S.E.
| GSK1 N | End-of-day quote | |
|
Deutsche Boerse AG
| GS71 | Delayed |
Last Transcript: GSK plc
| 1 day | -0.86% | ||
| 1 week | -3.86% | ||
| Current month | -2.87% | ||
| 1 month | -4.41% | ||
| 3 months | -11.20% | ||
| 6 months | -17.00% | ||
| Current year | -2.47% |
| 1 week | 1,770 |  | 1,917 |
| 1 month | 1,770 | | 1,917 |
| Current year | 1,690 | | 2,282 |
| 1 year | 1,592 | | 2,282 |
| 3 years | 1,242.5 | | 2,282 |
| 5 years | 1,242.5 | | 3,408.16 |
| 10 years | 1,242.5 | | 3,408.16 |
| Manager | Title | Age | Since |
|---|---|---|---|
Luke Miels
CEO | Chief Executive Officer | 52 | 01/01/2026 |
Julie Brown
DFI | Director of Finance/CFO | 64 | 01/05/2023 |
James Ford
CMP | Compliance Officer | - | 01/08/2018 |
| Director | Title | Age | Since |
|---|---|---|---|
Luke Miels
BRD | Director/Board Member | 52 | 06/05/2026 |
Hal Barron
BRD | Director/Board Member | 64 | 01/01/2018 |
Jonathan Symonds
CHM | Chairman | 67 | 01/09/2019 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 22/09/26 | Buy | Executive/Senior Manager | 9 | 0.0000% | ||
| 18/09/26 | Buy | Director | 768 | 0.0000% | ||
| 18/09/26 | Buy | Director | 1,734 | 0.0000% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -0.86% | -3.86% | +8.04% | +19.91% | 9.5TCr | |
| -0.61% | -3.43% | +39.40% | +112.31% | 1,02500Cr | |
| -1.02% | -5.60% | +37.67% | +65.02% | 62TCr | |
| +1.11% | -0.58% | +11.10% | +77.28% | 46TCr | |
| +0.34% | -3.01% | +61.21% | +40.71% | 35TCr | |
| -0.95% | -4.05% | +21.60% | +39.37% | 34TCr | |
| -1.46% | -2.89% | +11.84% | +24.60% | 27TCr | |
| -1.35% | -5.43% | -4.69% | +8.40% | 25TCr | |
| -1.04% | -2.79% | +35.52% | +51.34% | 22TCr | |
| -1.87% | -4.10% | +30.92% | +95.33% | 18TCr | |
| Average | -0.30% | -3.22% | +25.26% | +53.43% | 38.13TCr | |
| Weighted average by Cap. | +0.39% | -3.19% | +29.95% | +67.70% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 3.39TCr 4.49TCr 3.99TCr 3.72TCr 6.4TCr 4,31400Cr 6.46TCr 45TCr 17TCr 2,20500Cr 17TCr 16TCr 7,07800Cr | 3.55TCr 4.7TCr 4.17TCr 3.89TCr 6.69TCr 4,51500Cr 6.76TCr 47TCr 18TCr 2,30800Cr 18TCr 17TCr 7,40700Cr |
| Net income | 519.14Cr 686.83Cr 610.25Cr 569.57Cr 979.09Cr 66TCr 988.21Cr 6.89TCr 2.67TCr 34TCr 2.58TCr 2.52TCr 1,08300Cr | 620.94Cr 821.51Cr 729.92Cr 681.26Cr 1.17TCr 79TCr 1.18TCr 8.24TCr 3.19TCr 40TCr 3.08TCr 3.02TCr 1,29600Cr |
| Net Debt | 2.12TCr 2.81TCr 2.5TCr 2.33TCr 4.01TCr 2,70200Cr 4.04TCr 28TCr 11TCr 1,38100Cr 11TCr 10TCr 4,43300Cr | 1.85TCr 2.45TCr 2.18TCr 2.03TCr 3.49TCr 2,35500Cr 3.52TCr 25TCr 9.53TCr 1,20400Cr 9.2TCr 9TCr 3,86400Cr |
| Date | Price | Change | Volume |
|---|---|---|---|
| 02/26/02 | GBX 1,779.50 | -0.86% | 56,30,618 |
| 01/26/01 | GBX 1,795.00 | -2.02% | 85,93,783 |
| 30/26/30 | GBX 1,832.00 | -1.29% | 97,79,236 |
| 29/26/29 | GBX 1,856.00 | -0.22% | 84,86,430 |
| 28/26/28 | GBX 1,860.00 | +0.49% | 43,82,228 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- GSK Stock
Select your edition
All financial news and data tailored to specific country editions
